Invest. Engage. Save.

Rss

Coffee Break

Posted by: BIO Ventures for Global Health on 3/17/2010
BIO Ventures for Global Health CEO Melinda Moree moderated the panel Public/Private Partnerships: Impact on Live Science Innovation on March 17 at the Life Sciences Innovation Northwest Conference. Exploring how the public and private sectors can work together to improve the health of poor people in developing countries, panelists took a pragmatic look at public/private partnerships. They focused on commercially viable ways for the public and private sectors to work together.

Melinda was joined by Hannah Kettler, Program Officer, Global Health Policy and Finance, Bill & Melinda Gates Foundation; Hugh Chang, Director of Special Initiatives, PATH; Ken Stuart, President, Seattle Biomedical Research Institute; and Leander Lauffer, Head of Business Development, Malaria Vaccine Initiative.

The meeting organizers – Washington Biotechnology & Biomedical Association (WBBA) and Burrill & Company – are making it easy for you to get in on the action, even if you couldn't make it to Seattle. In partnership with Global Health Nexus Seattle, they are providing ON DEMAND webcast coverage of the event. Follow this link - http://ghnexus.dynamicwebcasting.net – to access the webcast.

The Life Sciences Innovation Northwest Conference, formerly know as Invest Northwest, is in its tenth year of highlighting the Pacific Northwest’s biotech and medical device industries. The meeting features the area’s diverse life science eco-system, and includes presentations, panels, and plenary sessions by leading experts from emerging and anchor device, diagnostic and biotech companies, premier research institutions, and our global health community.
Categories: Meetings
Create a trackback from your own site.
|   Blog Home

2 Comments

Aug 16 2010, 10:29 AM passport health indiana
The people of the developed countries are very much lucky to have a healthy life. BIO Ventures for Global Health CEO Melinda Moree was at the Life Sciences Innovation Northwest Conference to clearly discuss how they could be in help to the health of the people in the developing countries. I do hope and pray that the plans would work out better for the people who live in the other parts of the world.
Aug 17 2010, 12:09 AM handicap vans
The people of the developed countries are very much lucky to have a healthy life. BIO Ventures for Global Health CEO Melinda Moree was at the Life Sciences Innovation Northwest Conference to clearly discuss how they could be in help to the health of the people in the developing countries. I do hope and pray that the plans would work out better for the people who live in the other parts of the world.
Leave A Comment

Please enter the CAPTCHA phrase above.
 

Blog Home
  
  

Recent Comments

by simon on The Most Important Hire in Global Health
"I'd like to comment on the fact that the term "cost-effective" vaccines is not meaningful, since cost-effectiveness always depends on the Willigness to Pay of a given coutnry (which WHO recommends to be 1-3xGDP per capita). E.g. while in UK a medicines/vaccine that has incremental cost-effectiveness ratio of 43,000-130,000 USD/QALY will be considered "cost-effective", it will not be the case in India where the threshold is 1-3xGDP=1,000-3,000 USD/QALY. It means that the same vaccine would need to be 43x cheaper in India than in UK to be cost-effective. I believe that the future of developing countries will depend on their ability to develop vaccines locally and sell them at local prices. I am currently involved in a research project in India which aims at understanding the challenges of entrepreneurship and its role in affordable healthcare in the future. Best regards " Read more »

by Mark H on Trademark of Innovation
"Often the pharmaceutical companies are seen as evil because they do not do enough to help the poor by giving away medicines or licence rights. But we must consider two things: 1 they are commecial companies and have legal obligations towards their shareholders i.e. their prime concern is making money 2 these companies invest a vastly greater amount of money in R&D than the government. As a result their R&D occasionally finds cures inadvertently for other diseases - even if they are not actively trying to create the right medicine. So how do you create an incentive for the most effective creator of new innovative cures whose primary goal is to make money (like all companies)? Well the answer seems obvious - reward them with tax benefits that would help push them above their competitors. Whilst you could argue that this would prevent the government from reaping the benefits (tax) you could also say that the competition created would drive innovation and spending in the private sector which would improve the economy. A win win win situation - pharmaceuticals, government, developing countries!" Read more »

by BIO Ventures for Global Health on Ready to Go
"Thanks so much for your interest, Trudy. We are not currently working with the Carter Center but we are interested in speaking with them to gain epidemiological information for our Global Health Primer, and so hope to be working together in the future. " Read more »

  

Tag Cloud